Flibanserin Panel Review Will Pivot On Measurement Of Sexual Desire
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Reproductive Health Drugs Advisory Committee will weigh the best method for assessing the efficacy of Boehringer Ingelheim's Girosa for hypoactive sexual desire disorder in premenopausal women.
You may also be interested in...
Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says
Boehringer Ingelheim unable to show sufficient efficacy for Girosa in hypoactive sexual desire disorder in women.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.